(223 days)
No
The device description and performance studies detail a traditional immunoassay based on antibody binding and visual interpretation of a test line. There is no mention of algorithms, data processing, or any components typically associated with AI/ML.
No.
The InSure® ONE™ is a diagnostic device used to detect human hemoglobin from blood in fecal samples, aiding in the detection of lower gastrointestinal bleeding. It does not provide therapy or treatment.
Yes
Explanation: The InSure® ONE™ is explicitly stated as a "fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples" and is "used to aid in the detection of lower gastrointestinal bleeding." This directly indicates its role in identifying a medical condition or bleeding, which is a diagnostic purpose.
No
The device description clearly outlines physical components including test cards, brushes, test strips, and buffer solutions, indicating it is a hardware-based diagnostic test kit, not software only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The device is intended to "qualitatively detect human hemoglobin from blood in fecal samples" to "aid in the detection of lower gastrointestinal bleeding." This is a diagnostic purpose, providing information about a patient's health status.
- Sample Type: It analyzes "fecal samples," which are biological specimens taken from the human body.
- Testing Location: While the sample is collected at home, the test is "developed at laboratories or professional offices," indicating it's performed outside of the living body (in vitro).
- Device Description: The description details the components used to perform the test on the collected sample, including test strips with antibodies and a developer kit.
These characteristics align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic purposes.
N/A
Intended Use / Indications for Use
The InSure® ONE™ is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples. The samples will generally be collected by the test subject at home and the test developed at laboratories or professional offices. The InSure® ONE™ test is used to aid in the detection of lower gastrointestinal bleeding.
Product codes
KHE
Device Description
The InSure® ONE™ – One Day Fecal Immunochemical Test qualitatively detects human hemoglobin from blood in fecal samples. The fecal sample is generally collected by the test subject at home. Toilet bowl water samples are taken using long handled brushes to collect a small volume of water from around the defecated stool. The toilet water test sample once collected is placed on an InSure ONE Test Card. The InSure ONE Test Card then serves as a means to transport the dried samples to the laboratory. The InSure ONE test detects human hemoglobin in toilet bowl water. The test is developed in the laboratory or medical professional office with appropriate quality control. The FOBT Controls (K101831) are recommended for use as external controls.
Components of InSure® ONE™ - One Day Fecal Immunochemical Test:
- a. The InSure® ONE™ Collection Kit* contains:
- InSure® ONE™ Instructions for Use-Patient ●
- InSure® ONE™ Test Card ●
- Brush Kit containing 2x brushes and a waste bag ●
- Business reply form and envelope ●
- b. The InSure® ONE™ or InSure® FIT Developer Kit* (for development and interpretation of the test) contains:
- InSure® ONE™ Instructions for Use-Professional Laboratory .
- InSure® ONETM Test Strips: The Test Strips contain mouse monoclonal anti-. human hemoglobin test line antibodies and a conjugate-specific polyclonal (donkey anti-goat) antibody control line, and a conjugate of anti-human hemoglobin polyclonal (goat) antibodies bound to colored (colloidal gold) particles.
- . InSure® ONE™ Run Buffer: Contains borate salts, ethanol, bovine serum albumin, and sodium azide as preservative.
- c. The InSure® ONE™ or InSure® FIT FOBT Controls contains:
- · Instructions for Use
- · Positive Control
- · Negative Control
*The above kits and components are supplied in a variety of packaging configurations and sold in combination or separately to meet customer requirements.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Lower gastrointestinal
Indicated Patient Age Range
Not Found
Intended User / Care Setting
The samples will generally be collected by the test subject at home and the test developed at laboratories or professional offices.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
- Assay Cut-off Study: Fecal test samples were prepared by spiking stool samples with human blood of known hemoglobin concentration (0, 5, 10, 20, 30, 40, 50, 60, and 80 ug Hb/g stool). Pre-measured quantities of stool were placed in a pre-measured volume of water to simulate toilet water. Water samples were taken at 2 minutes with InSure sample collection brushes and applied to Test Cards using InSure FIT and InSure ONE sampling procedures. Testing was performed side-by-side with the predicate. Test Cards were prepared on Day 0, stored at room temperature (20-25°C) and developed on Day 5. The cut-off was determined to be 50 ug hemoglobin/g stool. Sample size: 40 samples per hemoglobin concentration level. Reliably detects 50ug hemoglobin/gram stool for up to 14 days after sample collection.
- Method Comparison: A method comparison of InSure® ONE™ with the predicate test, InSure® FIT™, was conducted to determine if there was a significant difference in test performance between sampling two separate fecal samples once each or a single fecal sampled twice. Patients were recruited from three intended use sites and the study was performed at one intended use site in Australia. A total of 859 patients collected fecal water samples using both InSure FIT and InSure ONE Test Cards before undergoing colonoscopy. Test Card A was the InSure FIT sampling procedure (predicate device). Test Card B and Test Card C was the InSure ONE sampling procedure (test device). Tissue samples collected at colonoscopy were histopathologically examined for the type of lesion. Statistical analysis of the test results for clinical positive predictive value (PPV) and clinical negative value (NPV) showed that the InSure ONE test results have acceptable overall agreement with InSure FIT test results. The study demonstrated that there were no statistically significant differences in the test results obtained from two fecal water sample aliquots taken from one bowel movement (new sampling method InSure ONE), when compared to one fecal water sample aliquot taken from two separate bowel movements (predicate sampling method InSure FIT).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Assay Cut-off Study Results:
| Hb Concentration (ng/mL) | N | InSure ONE | Negative Percent Agreement (95% CI1) | Positive Percent Agreement (95% CI1) |
|---|---|---|---|---|
| 0 | 40 | 40 | 100% (91.2% to 100%) | 0% (0% to 8.8%) |
| 5 | 40 | 38 | 95.0% (83.5% to 98.6%) | 5.0% (1.4% to 16.5%) |
| 10 | 40 | 31 | 77.5% (62.5% to 87.7%) | 22.5% (12.3% to 37.5%) |
| 20 | 40 | 19 | 47.5% (32.9% to 62.5%) | 52.5% (37.5% to 67.1%) |
| 30 | 40 | 8 | 20.0% (10.5% to 34.8%) | 80.0% (65.2% to 89.5%) |
| 40 | 40 | 3 | 7.5% (2.6% to 19.9%) | 92.5% (80.1% to 97.4%) |
| 50 | 40 | 1 | 2.5% (0.4% to 12.9%) | 97.5% (87.1% to 99.6%) |
| 60 | 40 | 1 | 2.5% (0.4% to 12.9%) | 97.5% (87.1% to 99.6%) |
| 80 | 40 | 0 | 0% (0% to 8.8%) | 100% (91.2% to 100%) |
| CI=confidence interval, Hb=hemoglobin. | ||||
| Method comparison showed acceptable overall agreement with InSure FIT test results for clinical positive predictive value (PPV) and clinical negative value (NPV). |
Predicate Device(s):
InSure® FIT™ (Fecal Immunochemical Test)
Reference Device(s):
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.6550 Occult blood test.
(a)
Identification. An occult blood test is a device used to detect occult blood in urine or feces. (Occult blood is blood present in such small quantities that it can be detected only by chemical tests of suspected material, or by microscopic or spectroscopic examination.)(b)
Classification. Class II (special controls). A control intended for use with an occult blood test is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized representation of three human profiles facing right, stacked on top of each other. The profiles are rendered in black and have a flowing, ribbon-like quality. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the profile graphic.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 13, 2017
ENTERIX INC. c/o RONALD SCHOENGOLD PRINCIPAL 19000 SARATOGA GLEN PLACE SARATOGA, CA 95070
Re: K170548
Trade/Device Name: InSure® ONE™ – One Day Fecal Immunochemical Test Regulation Number: 21 CFR 864.6550 Regulation Name: Occult blood test Regulatory Class: Class II Product Code: KHE Dated: August 28, 2017 Received: September 5, 2017
Dear Mr. Schoengold:
This letter corrects our substantially equivalent letter of October 5, 2017.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
1
medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Leonthena R. Carrington -S
Lea Carrington Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K170548
Device Name
InSure® ONE™ One Day Fecal Immunochemical Test
Indications for Use (Describe) Intended Use/Indications for Use
The InSure® ONE™ is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples. The samples will generally be collected by the test subject at home and the test developed at laboratories or professional offices. The InSure® ONE™ test is used to aid in the detection of lower gastrointestinal bleeding.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| ☑ Prescription Use (Part 21 CFR 801 Subpart |
|---|
| ☑ Over-The-Counter Use (21 CFR 801 Subpart |
D) InSure® ONE™ Developer Kit Components
☑ Over-The-Counter Use (21 CFR 801 Subpart
C) InSure® ONETM Sample Collection Kit
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for Clinical Genomics. The logo features a stylized human figure with a curved line extending from the figure's head down to the base. The text "Clinical Genomics" is written in a sans-serif font to the right of the figure. The color scheme is primarily black and blue.
510(k) Summary (As required by 21CFR 807.92)
Submitter Enterix Inc., A Clinical Genomics Inc. Company 236 Fernwood Avenue Edison, NJ 08837, USA 732 429 1899
Contact Person Michele Houldsworth, Vice President Regulatory Affairs
Date of Preparation September 30, 2017
Device Name InSure® ONE™ One Day Fecal Immunochemical Test
Common Name Fecal Occult Blood Test
Classification Name Fecal Immunochemical Test
Regulation Number 21 CFR 864.6550
Product Code KHE
Predicate Devices InSure® FIT™ (Fecal Immunochemical Test)
4
Device Description
The InSure® ONE™ – One Day Fecal Immunochemical Test qualitatively detects human hemoglobin from blood in fecal samples. The fecal sample is generally collected by the test subject at home. Toilet bowl water samples are taken using long handled brushes to collect a small volume of water from around the defecated stool. The toilet water test sample once collected is placed on an InSure ONE Test Card. The InSure ONE Test Card then serves as a means to transport the dried samples to the laboratory. The InSure ONE test detects human hemoglobin in toilet bowl water. The test is developed in the laboratory or medical professional office with appropriate quality control. The FOBT Controls (K101831) are recommended for use as external controls.
Components of InSure® ONE™ - One Day Fecal Immunochemical Test:
- a. The InSure® ONE™ Collection Kit* contains:
- InSure® ONE™ Instructions for Use-Patient ●
- InSure® ONE™ Test Card ●
- Brush Kit containing 2x brushes and a waste bag ●
- Business reply form and envelope ●
- b. The InSure® ONE™ or InSure® FIT Developer Kit* (for development and interpretation of the test) contains:
- InSure® ONE™ Instructions for Use-Professional Laboratory .
- InSure® ONETM Test Strips: The Test Strips contain mouse monoclonal anti-. human hemoglobin test line antibodies and a conjugate-specific polyclonal (donkey anti-goat) antibody control line, and a conjugate of anti-human hemoglobin polyclonal (goat) antibodies bound to colored (colloidal gold) particles.
- . InSure® ONE™ Run Buffer: Contains borate salts, ethanol, bovine serum albumin, and sodium azide as preservative.
- c. The InSure® ONE™ or InSure® FIT FOBT Controls contains:
- · Instructions for Use
- · Positive Control
- · Negative Control
*The above kits and components are supplied in a variety of packaging configurations and sold in combination or separately to meet customer requirements.
Intended Use
The InSure® ONE™ is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples. The samples will generally be collected by the test subject at home and the test developed at laboratories or professional offices. The InSure® ONETM test is used to aid in the detection of lower gastrointestinal bleeding.
Analytical Sensitivity
The InSure® ONE™ reliably detects 50ug hemoglobin/gram stool for up to 14 days after sample collection.
5
Assay Cut-off Study
Fecal test samples were prepared by spiking stool samples with human blood of known hemoglobin concentration, to obtain the following fecal hemoglobin concentrations: 0 ug Hb/g stool, 5 µg Hb/g stool, 10 µg Hb/g stool, 20 µg Hb/g stool, 30 µg Hb/g stool, 40 µg Hb/g stool, 50 ug Hb/g stool, 60 ug Hb/g stool and 80 ug Hb/g stool. Pre-measured quantities of stool spiked with different levels of hemoglobin were placed in a pre-measured volume of water to simulate toilet water in which stool will be deposited. Following deposition of the stool, water samples were taken at 2 minutes with the InSure sample collection brushes and applied to Test Cards using the InSure FIT and the InSure ONE sampling procedures. Testing was performed side-byside with the predicate by comparing the test results of the device with that of the predicate. Test Cards were prepared on Day 0, stored at room temperature (20-25°C) and developed on Day 5 to simulate the time span between the patient collecting the fecal water sample on the Test Card and transporting the sampled Test Card to the laboratory by mail. The cut-off was determined to be 50 ug hemoglobin/g stool.
| Hb
Concentration
(ng/mL) | N | InSure ONE | | Negative Percent
Agreement
(95% CI1) | Positive Percent
Agreement
(95% CI1) |
|--------------------------------|----|------------|----|--------------------------------------------|--------------------------------------------|
| 0 | 40 | 40 | 0 | 100%
(91.2% to 100%) | 0%
(0% to 8.8%) |
| 5 | 40 | 38 | 2 | 95.0%
(83.5% to 98.6%) | 5.0%
(1.4% to 16.5%) |
| 10 | 40 | 31 | 9 | 77.5%
(62.5% to 87.7%) | 22.5%
(12.3% to 37.5%) |
| 20 | 40 | 19 | 21 | 47.5%
(32.9% to 62.5%) | 52.5%
(37.5% to 67.1%) |
| 30 | 40 | 8 | 32 | 20.0%
(10.5% to 34.8%) | 80.0%
(65.2% to 89.5%) |
| 40 | 40 | 3 | 37 | 7.5%
(2.6% to 19.9%) | 92.5%
(80.1% to 97.4%) |
| 50 | 40 | 1 | 39 | 2.5%
(0.4% to 12.9%) | 97.5%
(87.1% to 99.6%) |
| 60 | 40 | 1 | 39 | 2.5%
(0.4% to 12.9%) | 97.5%
(87.1% to 99.6%) |
| 80 | 40 | 0 | 40 | 0%
(0% to 8.8%) | 100%
(91.2% to 100%) |
Cut-off Study
CI=confidence interval, Hb=hemoglobin
1 Wilson Score
6
Method Comparison
A method comparison of InSure® ONE™ with the predicate test, InSure® FIT™, was conducted to determine if there was a significant difference in test performance between sampling two separate fecal samples once each or a single fecal sampled twice, for detection of occult blood. Patients were recruited from three intended use sites and the study was performed at one intended use site in Australia. A total of 859 patients collected fecal water samples using both InSure FIT and InSure ONE Test Cards before undergoing colonoscopy. Test Card A was the InSure FIT sampling procedure, the predicate device. Test Card B and Test Card C was the InSure ONE sampling procedure, the test device.
Tissue samples collected at colonoscopy were histopathologically examined for the type of lesion (i.e., cancer, advanced adenoma, etc.). Statistical analysis of the test results for clinical positive predictive value (PPV) and clinical negative value (NPV) showed that the InSure ONE test results have acceptable overall agreement with InSure FIT test results. The study demonstrated that there were no statistically significant differences in the test results obtained from two fecal water sample aliquots taken from one bowel movement (new sampling method InSure ONE), when compared to one fecal water sample aliquot taken from two separate bowel movements (predicate sampling method InSure FIT). The InSure ONE test is substantially equivalent to the predicate device.
Summary
The InSure ONE One Day Fecal Immunochemical test has the same intended use, technological characteristics as the predicate device, InSure FIT. The InSure ONE is an easy to use screening method to reliably detect human hemoglobin from blood in toilet bowl water containing defecated stool that may be an indication of gastrointestinal pathology. The clinical performance of the InSure ONE sampling and test method support a substantial equivalence claim.